KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Income from Non-Controlling Interests (2017 - 2020)

Ionis Pharmaceuticals (IONS) has 5 years of Income from Non-Controlling Interests data on record, last reported at -$1.2 million in Q4 2020.

  • For Q4 2020, Income from Non-Controlling Interests fell 105.91% year-over-year to -$1.2 million; the TTM value through Sep 2021 reached -$1.2 million, up 92.19%, while the annual FY2020 figure was -$35.5 million, 489.21% down from the prior year.
  • Income from Non-Controlling Interests reached -$1.2 million in Q4 2020 per IONS's latest filing, up from -$12.1 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $19.5 million in Q4 2019 and bottomed at -$15.8 million in Q3 2018.
  • Average Income from Non-Controlling Interests over 4 years is -$4.9 million, with a median of -$8.4 million recorded in 2019.
  • Peak YoY movement for Income from Non-Controlling Interests: soared 51.09% in 2019, then plummeted 259.2% in 2020.
  • A 4-year view of Income from Non-Controlling Interests shows it stood at -$7.2 million in 2017, then crashed by 119.25% to -$15.8 million in 2018, then soared by 223.63% to $19.5 million in 2019, then plummeted by 105.91% to -$1.2 million in 2020.
  • Per Business Quant database, its latest 3 readings for Income from Non-Controlling Interests were -$1.2 million in Q4 2020, -$12.1 million in Q3 2020, and -$11.9 million in Q2 2020.